Interferon-γ inducible factor 16 (IFI16) restricts adeno-associated virus type 2 (AAV2) transduction in an

Sereina O Sutter1, Kurt Tobler1, Michael Seyffert1

  • 1Institute of Virology, University of Zurich, Zurich, Switzerland.

Journal of Virology
|June 5, 2024
PubMed

Insights

Interferon-gamma inducible factor 16 (IFI16) restricts adeno-associated virus type 2 (AAV2) infection and transduction. Silencing IFI16 enhances AAV2 efficiency by bypassing immune responses and interfering with Sp1-dependent gene expression.

Area of Science:

  • Molecular Virology
  • Gene Therapy
  • Innate Immunity

Background:

  • Adeno-associated virus (AAV) vectors are widely used in gene therapy due to their safety and efficacy.
  • Understanding virus-host interactions, particularly antiviral responses, is crucial for optimizing AAV vector applications.
  • Previous studies have not comprehensively analyzed the host cell's transcriptome response to AAV2 infection.

Purpose of the Study:

  • To investigate the host cell's transcriptional profile following adeno-associated virus type 2 (AAV2) infection in primary human fibroblasts.
  • To identify host factors involved in antiviral responses against AAV2 infection and transduction.
  • To elucidate the mechanism by which interferon-gamma inducible factor 16 (IFI16) influences AAV2 transduction.

Main Methods:

  • Transcriptome analysis of AAV2-infected primary human fibroblasts.
  • Validation of differentially expressed genes using various molecular assays.
  • Assessment of AAV2 transduction efficiency following manipulation of IFI16 expression.

Main Results:

  • AAV2 infection significantly alters host cell pathways, including cell cycle regulation, chromatin modulation, and innate immune responses.
  • Interferon-gamma inducible factor 16 (IFI16) is upregulated upon AAV2 infection and acts as a restriction factor.
  • Post-transcriptional silencing of IFI16 enhances AAV2 transduction efficiency independently of genome structure and immune modulation, by interfering with Sp1-dependent promoter activity.

Conclusions:

  • IFI16 functions as a critical antiviral factor against AAV2 infection and vector-mediated transduction.
  • IFI16 inhibits AAV2 transduction through an immune-modulatory independent mechanism involving Sp1-dependent transactivation.
  • Targeting IFI16 may represent a strategy to improve AAV vector-based gene therapies.